LAMTIDINE is an irreversible and specific gastric histamine H2-receptor antagonist.

Disogluside (Trillin) is an active ingredient isolated from Dioscorea nipponica Makino. Trillin reduces liver chronic inflammation and fibrosis in carbon tetrachloride (CCl4) induced liver injury in mice. Trillin exhibited protective effect on LPS-induced ALI by the regulations of related inflammatory events via the activations of Nrf2, HO-1 and NF-κB pathway. Trillin has being shown to exert protective effects against hyperlipidemia and oxidative stress. Trillin induced multinucleation in HL-60, NB4 and K562 cells, indicating it could induce mitotic arrest in these leukemia cells.

Butoxylate is organic compound with significant analgesic or mydriatic activity after s.c. injection in mice and rats

Propinetidine is a piperidinol derivative patented by Farbenfabriken Bayer Akt.-Ges. as antitussive agent.

Clanobutin is a choleretic drug. It increases the secretion of bile by hepatocytes. Clanobutin sodium has been introduced as a choleretic and digestant agent for animals. It has been used in all domestic animals in which enhancement of digestion and all associated secretory processes are indicated. Clanobutin was reported to induce a demonstrable increase in the secretory activity of the exocrine digestive glands and in the excretion of the bile.

Piragliatin is a nonessential, mixed-type (i.e. increases maximal velocity and affinity of glucokinase for glucose) small-molecule activators of glucokinase. Preclinical pharmacology studies confirmed that piragliatin had activity in both pancreatic beta-cell and hepatic cell glucose metabolism. Piragliatin augmented glucose-stimulated insulin secretion (GSIS) in human islets from both normal individuals and patients with type 2 diabetes, primarily by left-shifting the glucose dependency curve of GSIS. In healthy volunteers a single administration of piragliatin showed dose-dependent reduction of fasting plasma glucose. The glucokinase activator piragliatin has an acute glucose-lowering action in patients with mild type 2 diabetes, mainly mediated through a generalized enhancement of beta-cell function and through fasting restricted changes in glucose turnover. Headache and mild hypoglycemia were the most frequent adverse events associated with piragliatin treatment. The effect of piragliatin treatment on the QTc interval was dose/exposure dependent following short-term multiple doses. Piragliatin had been in phase II clinical trial for the treatment of Type 2 diabetes mellitus. However, this development was discontinued.

Cinprazole (7110 MD) is an investigational benzimidazole derivative, discovered by Delalande S. A in 1972. The compound shows notable gastric antisecretory and antiulcer activity most likely due to a peripheral anti-acetylcholine action. Cinprazole also shows local anesthetic activity on rabbit cornea, and has no effect on the central nervous system in the mouse, rat and rabbit, or on the respiration in the rabbit.

Cetaben has been identified as an anti-atherosclerotic hypolipidaemic substance. Cetaben is a unique, PPARα-independent peroxisome proliferator with hypolipidemic activity that inhibits cholesterol synthesis in the human hepatoma Hep-G2 cells resulting in reversible changes in Golgi morphology. Cetaben represents an exceptional type of peroxisome proliferator, specifically affecting peroxisomes, without having a negative influence on the processes of peroxisome biogenesis. Cetaben raised only the peroxisomal enzymes, acyl-CoA oxidase, glycerone-phosphate acyltransferase, D-amino-acid oxidase, catalase, and urate oxidase. Cetaben sodium has being shown to be an antiatherosclerotic agent.

Oxoprostol was developed as a gastric acid secretion inhibitor. Information about the further development of this drug is not available.